Compounded semaglutide is not outright illegal for medspas, but it is legally precarious and carries real enforcement risk. The FDA has not banned compounding pharmacies from making semaglutide, yet the agency has made clear that compounding is permitted only when there is a documented shortage of an FDA-approved equivalent—a condition that no longer exists for semaglutide. This distinction matters enormously for medspas sourcing the drug.

The Shortage Justification Has Expired